Venus Medtech (Hangzhou) Inc. (HKG:2500)
3.010
-0.370 (-10.95%)
At close: Jan 21, 2026
Venus Medtech (Hangzhou) Revenue
Venus Medtech (Hangzhou) had revenue of 187.14M CNY in the half year ending June 30, 2025, a decrease of -26.79%. This brings the company's revenue in the last twelve months to 427.25M, down -8.41% year-over-year. In the year 2024, Venus Medtech (Hangzhou) had annual revenue of 470.83M, down -4.18%.
Revenue (ttm)
427.25M CNY
Revenue Growth
-8.41%
P/S Ratio
2.82
Revenue / Employee
618.31K CNY
Employees
691
Market Cap
1.32B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 470.83M | -20.54M | -4.18% |
| Dec 31, 2023 | 491.37M | 84.91M | 20.89% |
| Dec 31, 2022 | 406.46M | -9.40M | -2.26% |
| Dec 31, 2021 | 415.86M | 139.82M | 50.65% |
| Dec 31, 2020 | 276.05M | 42.78M | 18.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |